Oser Communications Group

Chain Drug Store Annual Meeting Apr 25 2015

Issue link: http://osercommunicationsgroup.uberflip.com/i/499803

Contents of this Issue

Navigation

Page 28 of 31

C h a i n D r u g s t o r e D a i l y 2 9 S a t u r d a y, A p r i l 2 5 , 2 0 1 5 shipped, it's really just part of the culture here at Camber. CDD: Is this commitment reflected in your results for 2014? KO: Yes, definitely. Based on the latest IMS data, Camber is number 14 overall among generic companies in dispensed prescriptions and number 1 in percent growth with an 18.9 percent increase for 2014. We are very proud of these accom- plishments but we're not the type of com- pany to rest on our laurels. CDD: Tell us about your parent compa- ny, Hetero Drugs. KO: As the Chairman of Hetero, Dr. B.P.S Reddy likes to say, 'We are in the life sav- ing business.' Hetero's business model is based on providing affordable, lifesaving medications to as many people as possi- ble. An example of that is their dedication to improving the quality of life for HIV patients worldwide. In addition to being a member of PEPFAR (Presidents Emergency Plan for AIDS Relief), Hetero and Camber currently provide anti-retro- viral medications to some 3.5 million patients in 140 countries. Hetero is also Camber Pharmaceuticals (Cont'd. from p. 1) one of the largest API manufacturers in the world, which gives Camber a distinct advantage when it comes to maintaining the integrity of our supply chain. CDD: What plans does Camber have for 2015? KO: For 2015 we are planning an aggressive new product launch schedule. We have already launched four new products since January (Valsartan, Zolmitriptan, Pantoprazole and Rizatriptan), and we have 20 or so more in the pipeline. We have also launched a new OTC division of Camber Pharmaceuticals called Camber Consumer Care, which will focus on the pain, allergy, sleep and cough/cold cate- gories. We believe our current success, great reputation and strong existing cus- tomer relationships will give us a good opportunity to break into and thrive in the competitive OTC marketplace. At the end of the day, it is our quality products, commitment to teamwork and passion for the business that will drive Camber's continued growth. Visit Camber at booth #534. For more information, visit www.camberpharma.com or call 732.529.0430. customers for at least another 10 years of service. There aren't many technologies that have stood the test of time like that. CDD: We understand that ScriptPro is now more than a robot company. Tell us a little about that. MC: ScriptPro is a one-stop shop for sys- tems to operate pharmacies of all types and sizes. Our customers include chains, independents, health systems and mail service/central fill operations. We also offer a hosted third party management system that is actually a full revenue accounting platform. It can be used with any pharmacy management system and provides everything needed for financial management of pharmacy revenues. CDD: How about the latest hot topics – like 340B and specialty pharmacy? MC: We have unique offerings in these areas. Our pharmacy management system has built-in real time 340B processing. The system identifies the 340B prescrip- tions and directs pharmacy staff to select the optimum priced products from inven- tory. It automatically enters the correct ScriptPro (Cont'd. from p. 1) codes for claims submission. There is a virtual class of trade inventory tracking and automated ordering. Other systems rely on after the fact processing to track and replenish 340B inventory and correct the claims. These approaches are compli- cated and error prone and they cannot deal with the fact that the patient has already left the pharmacy with the wrong drug. We also have a unique approach to specialty pharmacy with integration of workflow checks, advanced DUR processes and case management tools with the pharmacy management system. Other approaches rely on add-on pack- ages and duplication of data entry to han- dle specialty pharmacy and complicated medication therapy support. CDD: What does all this mean to the business of running pharmacies? MC: Like all businesses, pharmacies need to grapple with fundamental issues: how to increase margins, reduce costs and expand access to patients. In the changing healthcare landscape, powerful systems are required to do this. For more information, visit booth #449 or contact them at www.scriptpro.com or call 800.606.7628. the complete family of generic PEG- 3350 products, and is one more example of how GAVIS is listening – and deliver- ing – what patients, physicians and phar- macists want: a choice. The dosage form includes a 2-liter container, Flavor Pack, GaviLyte-H pow- der and Bisacodyl tablet. About GAVIS Pharmaceuticals GAVIS Pharmaceuticals is a leading company in the formulation, develop- ment, manufacturing, packaging, sales, marketing and distribution of first-class generic pharmaceuticals. Founded in 2008 by industry veteran, Dr. Veerappan Subramanian, GAVIS Pharmaceuticals develops, markets and, in conjunction with its sister company Novel Laboratories of Somerset, N.J., manufac- tures niche, specialty and difficult-to- make products across a range of thera- peutic classes and dosage forms. With a trusted team of experienced professionals that have 300+ years of generic pharmaceutical experience, GAVIS is dedicated to bringing niche products to market first. GAVIS delivers value to its retail pharmacy partners by identifying the needs of patients, pre- GAVIS Pharmaceuticals (Cont'd. from p. 1) scribers and pharmacies, and delivering products that offer therapeutic, economic or continuity benefits to everyone involved. Often, these are products for which no generic version is available. GAVIS is focused on product safety and conducts comprehensive safety monitoring and evaluation throughout all stages of its product lifecycle. It is also committed to the safe and efficacious use of its products. Its development portfolio focuses on products for gastrointestinal, women's health and controlled drug substances across a range of dosage forms including modified-release tablets and capsules, orally-disintegrating tablets, chewable tablets, immediate release tablets and capsules, non-sterile liquids and suspen- sions, sachets, powders, semi-solids, top- ical solutions, rectal gels and rectal sup- positories. GAVIS launched its first three prod- ucts in May 2009 and distributes its prod- ucts from a state-of-the-art, 150,000- square-foot warehouse facility in Somerset, N.J. Since its debut, GAVIS has built – and will continue to expand – a robust pipeline of specialty pharmaceu- ticals with limited competition. For more information, visit www .gavilyte.com or www.gavispharma.com. in Topicals, including solutions, oint- ments, gel and creams, to ensure quality in every product. The $4.2 billion Transdermal market includes hydrogel and matrix patches and form-fill seals while Inhalation forms such as Dry Powder Inhalers (DPIs) with multi-component, highly-sophisticated designs and Metered Dose Inhalers (MDIs) whose complex design requires precision engineering for pumps, meter- ing valves and dose counters, are impor- tant patient aids. Injectables for general purpose and oncologic therapies include products such as microspheres and pen devices that can help patients manage chronic conditions. Microspheres deliver a cus- tomized, sustained release of proteins, peptides and other medical components for extended treatment regimens while pen injection systems offer convenience and compliance support for patients as well as time and cost savings for health- care providers and payers. Intranasal dosage forms like sprays and solutions and Otics, ophalmics and transucosals, along with other niche dosage forms, round out the complex system of dosage forms that Amneal Pharmaceuticals has expe- rience working in. The unique products involve com- plex molecules and high-precision Amneal Pharmaceuticals (Cont'd. from p. 4) devices with difficult formulation, process and manufacturing requirements plus a complicated regulatory pathway. It is a high barrier-to-entry segment with numerous first-to-market "whitespace" opportunities where there is no generic penetration. With 21 of Amneal's injectable products in the pipeline representing a market size of $12.6 billion dollars, the company plans to support its current portfolio and extensive pipeline of future products by investing more than $600 million in research and develop- ment as well as capital expenditures over the next two years. When facility expansions are completed, finished products manufacturing space will exceed one million square feet with an output of approximately 30 billion units annually. Amneal's strategic decision to focus its business resources on each dosage form it supplies is just the latest example of how the company pursues "intelligent growth." This alignment results in strong commitment and execution in each cate- gory, as well as employees' ownership of success, to ensure the consistently superb product quality and outstanding service levels for which this generics industry leader is known. Stop by for more information at booth #202 and www.amneal.com or call 866.525.7270. high productivity on the shelf and an honest spend." Biernbaum explained further, "And I take on only clients that give me the room and the mandate to go to market the right way, with no undermining, and they must allow me to surround them with other champions that I know, trust and have worked with for years." David Biernbaum is extremely well connected. In 2009, he started up the Consumer Goods & Retail Professionals networking group on LinkedIn that now has more than 55,000 members and con- tributes every morning as a "BrainTrust panel member" on the popular Retailwire.com blog as well as holding a number of committee positions at NACDS and in other trade associations. Biernbaum is passionate about the CPG retail industry and enjoys his long history bringing success and profits not David Beirnbaum (Cont'd. from p. 4) only to his own clients and brands, but also to his retail partners. "Retail category managers and exec- utives are thrilled with the profits being made on destination-items like Australian Dream and TriCalm. My clients' brands not only are making big profits but are the ones making the dis- ruptive difference in the aisle while bringing in the most coveted premium customer that spends the most money in the store." Of the numerous products that have benefited from his approach, a few older brands that David and his teams have guided or helped influence include ZarBee's children's cough syrups, Zooth licensed toothbrushes, Aquafresh, Oral- B, Selsun Blue, Gillette Sensor, Germ-X, Sonicare and TheraBreath. For more information, visit www.consult davidb.com, call 314.434.6008 or email david@biernbaum.com.

Articles in this issue

Links on this page

view archives of Oser Communications Group - Chain Drug Store Annual Meeting Apr 25 2015